Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 328 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 2017;40:855-69. [Ref.ID 102075]
2. Cita con resumen
Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, Smeeth L. Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. BMJ 2017;358:j3334. [Ref.ID 101997]
3. Cita con resumen
Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]
4. Cita con resumen
Rosenberg HG, Shnier A. Regulatory data are hidden in plain sight. BMJ 2017;358:j3437. [Ref.ID 101980]
5. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
6. Cita con resumen
Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings—A cross-sectional study. JAMA Intern Med 2017;177:1038-40. [Ref.ID 101664]
7. Cita con resumen
8. Cita con resumen
Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]
9. Cita con resumen
Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:28 de junio. [Ref.ID 101657]
11. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
12. Cita con resumen
Anónimo. UK’s NICE recommends ibrutinib after discount. DIA Daily 2016:2. [Ref.ID 100979]
14. Cita con resumen
Anónimo. EMA releases clinical trial data in transparency effort. DIA Daily 2016:1. [Ref.ID 100849]
17.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
18.Enlace a cita original Cita con resumen
Anónimo. La falsa transparencia y el lavado de cara de la industria farmacéutica. NoGracias 2016:1 de julio. [Ref.ID 100507]
19. Cita con resumen
Anónimo. NICE endorses bosutinib for treatment of myeloid leukemia. DIA Daily 2016:3. [Ref.ID 100484]
20. Cita con resumen
Anónimo. EU ombudsman: EMA should release adalimumab data. DIA Daily 2016:1. [Ref.ID 100412]
Seleccionar todas
 
 1 a 20 de 328 siguiente >>